000 01455 a2200409 4500
005 20250516122254.0
264 0 _c20130501
008 201305s 0 0 eng d
022 _a1744-7623
024 7 _a10.1517/14728214.2012.748036
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBalasegaram, Manica
245 0 0 _aLiposomal amphotericin B as a treatment for human leishmaniasis.
_h[electronic resource]
260 _bExpert opinion on emerging drugs
_cDec 2012
300 _a493-510 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAmphotericin B
_xadministration & dosage
650 0 4 _aAntiprotozoal Agents
_xadministration & dosage
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aDrug Design
650 0 4 _aDrugs, Generic
_xtherapeutic use
650 0 4 _aHealth Services Accessibility
650 0 4 _aHumans
650 0 4 _aLeishmaniasis
_xdrug therapy
650 0 4 _aLeishmaniasis, Visceral
_xdrug therapy
650 0 4 _aTherapeutic Equivalency
700 1 _aRitmeijer, Koert
700 1 _aLima, Maria Angeles
700 1 _aBurza, Sakib
700 1 _aOrtiz Genovese, Gemma
700 1 _aMilani, Barbara
700 1 _aGaspani, Sara
700 1 _aPotet, Julien
700 1 _aChappuis, François
773 0 _tExpert opinion on emerging drugs
_gvol. 17
_gno. 4
_gp. 493-510
856 4 0 _uhttps://doi.org/10.1517/14728214.2012.748036
_zAvailable from publisher's website
999 _c22279287
_d22279287